Fernanda Paola Pons-Faudoa

Fernanda Paola Pons-Faudoa

Auto-generated profile, based on publicly available information

Fernanda Paola Pons-Faudoa

Houston Methodist Research Institute

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2019 in Biomedical Microdevices
Verified
Journal Article
Closed access
PDF file
FPFernanda P. Pons-Faudoa
Fernanda P. Pons-Faudoa
ABAndrea Ballerini
Andrea Ballerini
JSJason Sakamoto
Jason Sakamoto
Alessandro GrattoniAlessandro Grattoni
Alessandro Grattoni

26 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JPJesus Paez-Mayorga
Jesus Paez-Mayorga
JCJocelyn Nikita Campa-Carranza
Jocelyn Nikita Campa-Carranza
SCSimone Capuani
Simone Capuani
NHNathanael Hernandez
Nathanael Hernandez
HLHsuan-Chen Liu
Hsuan-Chen Liu
Alessandro GrattoniAlessandro Grattoni
Alessandro Grattoni
Pancreatic islet transplantation efficacy for type 1 diabetes (T1D) management is limited by hypoxia-related graft attrition and need for systemic immunosuppression. To overcome these challenges, we developed the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) device, which integrates direct vascularization for facile mass transfer and localized immunosuppressant delivery for islet rejection prophylaxis. Here, we investigated NICHE efficacy for allogeneic islet transplantation and long-term diabetes reversal in an immunocompetent, male rat model. We demonstrated that allogeneic islets transplanted within pre-vascularized NICHE were engrafted, revascularized, and functional, reverting diabetes in rats for over 150 days. Notably, we confirmed that localized immunosuppression prevented islet rejection without inducing toxicity or systemic immunosuppression. Moreover, for translatability efforts, we showed NICHE biocompatibility and feasibility of deployment as well as short-term allogeneic islet engraftment in an MHC-mismatched nonhuman primate model. In sum, the NICHE holds promise as a viable approach for safe and effective islet transplantation and long-term T1D management.

25 May 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
FPFernanda P. Pons-Faudoa
Fernanda P. Pons-Faudoa
ASAntons Sizovs
Antons Sizovs
NTNicola Di Trani
Nicola Di Trani
JPJesus Paez-Mayorga
Jesus Paez-Mayorga
GBGiacomo Bruno
Giacomo Bruno
Alessandro GrattoniAlessandro Grattoni
Alessandro Grattoni

16 December 2020 in Advanced Therapeutics
Verified
Journal Article
Open access
PDF file
FPFernanda P. Pons‐Faudoa
Fernanda P. Pons‐Faudoa
ASAntons Sizovs
Antons Sizovs
KSKathryn A. Shelton
Kathryn A. Shelton
ZMZoha Momin
Zoha Momin
JNJean A. Niles
Jean A. Niles
Alessandro GrattoniAlessandro Grattoni
Alessandro Grattoni
Pre‐exposure prophylaxis (PrEP) using antiretroviral oral drugs is effective at preventing human immunodeficiency virus (HIV) transmission when individuals adhere to the dosing regimen. Tenofovir alafenamide (TAF) is a potent antiretroviral drug, with numerous long‐acting (LA) delivery systems under development to improve PrEP adherence. However, none has undergone preventive efficacy assessment. Here it is shown that LA TAF using a novel subcutaneous nanofluidic implant (nTAF) confers partial protection from HIV transmission. It is demonstrated that sustained subcutaneous delivery through nTAF in rhesus macaques maintains tenofovir diphosphate concentration at a median of 390 fmol per 10 6 peripheral blood mononuclear cells, nine times above clinically protective levels. In a non‐blinded, placebo‐controlled rhesus macaque study with repeated low‐dose rectal simian HIV SF162P3 (SHIV SF162P3 ) challenge, the nTAF cohort has a 62.50% reduction (95% CI: 1.72–85.69%; p = 0.068) in risk of infection per exposure compared to the control. This finding mirrors that of tenofovir disoproxil fumarate (TDF) monotherapy, where 60% protective efficacy is observed in macaques, and clinically, 67% reduction in risk with 86% preventive efficacy in individuals with detectable drug in the plasma. Overall, this nanofluidic technology shows potential as a subcutaneous delivery platform for long‐term PrEP and provides insights for clinical implementation of LA TAF for HIV prevention.

1 February 2019 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
NTNicola Di Trani
Nicola Di Trani
PJPriya Jain
Priya Jain
CCCorrine Ying Xuan Chua
Corrine Ying Xuan Chua
JHJeremy S. Ho
Jeremy S. Ho
GBGiacomo Bruno
Giacomo Bruno
Alessandro GrattoniAlessandro Grattoni
Alessandro Grattoni

28 June 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
FPFernanda P. Pons-Faudoa
Fernanda P. Pons-Faudoa
NTNicola Di Trani
Nicola Di Trani
SCSimone Capuani
Simone Capuani
JCJocelyn Nikita Campa-Carranza
Jocelyn Nikita Campa-Carranza
BNBharti Nehete
Bharti Nehete
Alessandro GrattoniAlessandro Grattoni
Alessandro Grattoni
The impact of pre-exposure prophylaxis (PrEP) on slowing the global HIV epidemic hinges on effective drugs and delivery platforms. Oral drug regimens are the pillar of HIV PrEP, but variable adherence has spurred development of long-acting delivery systems with the aim of increasing PrEP access, uptake, and persistence. We have developed a long-acting subcutaneous nanofluidic implant that can be refilled transcutaneously for sustained release of the HIV drug islatravir, a nucleoside reverse transcriptase translocation inhibitor that is used for HIV PrEP. In rhesus macaques, the islatravir-eluting implants achieved constant concentrations of islatravir in plasma (median 3.14 nM) and islatravir triphosphate in peripheral blood mononuclear cells (median 0.16 picomole per 10 6 cells) for more than 20 months. These drug concentrations were above the established PrEP protection threshold. In two unblinded, placebo-controlled studies, islatravir-eluting implants conferred 100% protection against infection with SHIV SF162P3 after repeated low-dose rectal or vaginal challenge in male or female rhesus macaques, respectively, compared to placebo control groups. The islatravir-eluting implants were well tolerated with mild local tissue inflammation and no signs of systemic toxicity over the 20-month study period. This refillable islatravir-eluting implant has potential as a long-acting drug delivery system for HIV PrEP.